HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $20.88 Average Price Target from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has received an average recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $20.8750.

HCM has been the subject of several research reports. Morgan Stanley downgraded HUTCHMED from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $18.00 to $13.75 in a research report on Monday, September 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th.

HUTCHMED Trading Up 4.8%

Shares of HCM opened at $16.05 on Friday. HUTCHMED has a 12-month low of $11.51 and a 12-month high of $19.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. The company has a 50-day moving average of $14.16 and a two-hundred day moving average of $15.43.

Institutional Investors Weigh In On HUTCHMED

A number of hedge funds and other institutional investors have recently modified their holdings of HCM. ABN Amro Investment Solutions purchased a new stake in HUTCHMED in the 2nd quarter worth approximately $962,000. Vanguard Personalized Indexing Management LLC lifted its stake in shares of HUTCHMED by 23.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock worth $233,000 after purchasing an additional 2,916 shares during the period. Goldman Sachs Group Inc. increased its stake in HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares during the last quarter. Tema Etfs LLC purchased a new position in HUTCHMED during the second quarter worth about $641,000. Finally, M&G PLC boosted its stake in HUTCHMED by 0.4% in the 2nd quarter. M&G PLC now owns 259,617 shares of the company’s stock worth $3,894,000 after buying an additional 924 shares during the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.